2025 年 6 月 4 日,吉利德科学(Gilead Sciences)正全力备战,欲在 200 亿美元规模的多发性骨髓瘤 CAR-T 市场中挑战强生(Johnson & Johnson)的主导地位。尽管强生凭借 CAR-T 疗法 Carvykti 已占据先发优势,但吉利德寄望以更优的安全性和相当的疗效,配合门诊治疗模式和成熟的生产网络,在这一快速增长的市场中抢占份额。一、200 亿市场争夺战:...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.